Antidotes edge closer to reversing effects of new blood thinners

  title={Antidotes edge closer to reversing effects of new blood thinners},
  author={Elie S. Dolgin},
  journal={Nature Medicine},
  • E. Dolgin
  • Published 1 March 2013
  • Medicine
  • Nature Medicine
The US approval late last year of the blood thinner Eliquis (apixaban) made it the third blood-thinner pill option to come online in the last three years, all of which have proven to be as or more effective as the old go-to warfarin, with lower rates of brain hemorrhaging and fewer blood tests required to get the dosing right. However, unlike warfarin, which has an antidote in the form of vitamin K, no compounds exist that directly counteract the anticoagulation effects of these next-generation… 

Structural and functional characterization of a specific antidote for ticagrelor.

The identification and the in vitro and in vivo pharmacology of an antigen-binding fragment (Fab) antidote for ticagrelor were presented and this specific antidote may prove valuable as an agent for patients who require emergency procedures.

Decision-making about the use of non-vitamin K oral anticoagulant therapies for patients with atrial fibrillation

  • M. Eckman
  • Medicine
    Journal of Thrombosis and Thrombolysis
  • 2015
A patient-centered/shared decision-making approach will be useful in light of the many complex and nuanced issues surrounding the choice of an optimal anticoagulant for any AF patient.

Newer Oral Anticoagulants

These drugs have totally changed the way the patients suffering from thrombosis are treated and are very useful and effective but have lots of limitations, which complicate its management.

Dabigatran Excess: Case Report and Review of the Literature

The authors review the use of dabigatran in elderly patients, the available data on management of patients with excess anticoagulation, and the potential options for reversal of the antICOagulation effect.

Direct oral anticoagulants and their clinical management

Thrombotic disorders are treated mostly with Heparin and Warfarin in cases requiring anticoagulation drugs, but many antidotes have been developed to reverse these DOACs.

Reversal strategies for non-vitamin K antagonist oral anticoagulants: a critical appraisal of available evidence and recommendations for clinical management—a joint position paper of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology

The risk of bleeding in patients managed with NOACs was properly assessed in the four landmark Phase III trials in patients with atrial fibrillation (AF); major bleeding was the principal safety outcome in RE-LY,3,4 ARISTOTLE,5 and ENGAGE AF.

THROMBOSIS AND HEMOSTASIS Structural and functional characterization of a speci fi c antidote for

An antidote for ticagrelor is presented that reverses its antiplatelet effect in human platelet-rich plasma and its bleeding effect in mice.

Design, synthesis and biological evaluation of novel 2,3-dihydroquinazolin- 4(1H)-one derivatives as potential fXa inhibitors.

Roflumilast ( Daliresp ® ) : A Selective Phosphodiesterase-4 Inhibitor for the Prevention of Acute Exacerbations of Chronic Obstructive Pulmonary Disease

A direct relationship exists between the severity of disease, characterized by acute exacerbations and hospitalizations, and the total cost of care; and Prevention of AECOPDs is a major focus of disease management.